Answers are grounded in this paper and cite their sources.
This exploratory study shows that genetic polymorphisms in three genes involved in sunitinib pharmacokinetics are associated with PFS in mRCC patients treated with this drug. These findings advocate prospective validation and further elucidation of these genetic determinants in relation to sunitinib exposure and efficacy.
No takes yet. Share an insight, caveat, or question.
Veldt et al. (2010) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: